Bedrocan (BED on the TSX-V) management discussed:

• MMPR opportunity and supply/demand dynamics in the Canadian MMJ market
• The relationship with Bedrocan BV
• Bedrocan Canada's strategy
• Why the company offers just 5 strains
• The company's efforts to establish credibility with physicians
• The current number of customers
• Capacity expansion plans
• Capital structure
• Potential for listing in the U.S.
• Opportunity to expand brand to the U.S.
• The insight gained from serving as Chairman of the CMCIA

Marc Wayne, CEO, who spent 5 years as Director of Business Development at the Canadian Consortium for the Investigation of Cannabinoids before starting Bedrocan Canada in 2012. Marc is also a founding member and the Chairman of the industry trade group, the Canadian Medicinal Cannabis Industry Association.

Michael Singer, CFO, who joined Bedrocan Canada earlier this year after serving for more than a decade as CFO of Thallion Pharmaceuticals and its predecessor, in addition to holding several Board of Director positions in both public and private life sciences companies.

Cam Battley, VP Communications, who has run an independent global healthcare consulting group since 1997 and was formerly Director of Communications for Eli Lilly pharmaceuticals.

For more info: